#SGMO hashtag - Bluesky

Sangamo Therapeutics Announces Fourth Quarter and Full Year 2025 Earnings Call Sangamo Therapeutics (Nasdaq: SGMO) said it will release its fourth quarter and full year 2025 financial results after market close on Monday, March 30, 2026. A public conference call and webcast is set for 4:30 p.m. Eastern on March 30, 2026, followed by a replay available under Events.Participants must register to receive dial‑in numbers and a unique passcode or use a dial‑out option; the live webcast link is on the company website in Investors and Media.

3 weeks ago

#SGMO Sangamo Therapeutics Announces Fourth Quarter and Full Year 2025 Earnings Call

www.stocktitan.net/news/SGMO/sangamo-therap...

0 0 0 0

Sangamo Therapeutics Advances Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease Data support potential of isaralgagene civaparvovec as a one-time, well tolerated and durable Fabry disease gene therapy to provide meaningful, multi-organ clinical benefits that could fundamentally shift Fabry treatment paradigm STAAR study demonstrated positive mean annualized estimated

1 month ago

#SGMO Sangamo Therapeutics Advances Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease

www.stocktitan.net/news/SGMO/sangamo-therap...

0 0 0 0

Sangamo Therapeutics Initiates Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease Sangamo Therapeutics (Nasdaq: SGMO) has initiated a rolling submission of a Biological License Application (BLA) to the U.S. FDA seeking accelerated approval for isaralgagene civaparvovec (ST-920) to treat adults with Fabry disease.The registrational STAAR study showed a positive mean annualized eGFR slope at 52 weeks across dosed patients, and the FDA agreed that eGFR slope will serve as an endpoint to support accelerated approval. Sangamo expects to complete the BLA submission under the accelerated pathway in Q2 2026. ST-920 has received Orphan Drug, Fast Track, and RMAT designations from the FDA and regulatory recognitions from EMA and UK regulators.

3 months ago

#SGMO Sangamo Therapeutics Initiates Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease

www.stocktitan.net/news/SGMO/sangamo-therap...

0 0 0 0

Sangamo Therapeutics Receives U.S. FDA Fast Track Designation for ST-503 for the Treatment of Small Fiber Neuropathy Sangamo Therapeutics (NASDAQ: SGMO) announced that the U.S. FDA granted Fast Track Designation to ST-503 for the treatment of intractable pain from small fiber neuropathy (SFN).The designation may enable more frequent FDA interactions and could make ST-503 eligible for Accelerated Approval or Priority Review if criteria are met. ST-503 is an investigational epigenetic regulator currently in the Phase 1/2 STAND study, with patient recruitment underway and first dosing expected in the coming months. Sangamo previously presented nonclinical data showing durability, potency, selectivity and a favorable safety profile in nonhuman primates.

4 months ago

#SGMO Sangamo Therapeutics Receives U.S. FDA Fast Track Designation for ST-503 for the Treatment of Small Fiber Neuropathy

www.stocktitan.net/news/SGMO/sangamo-therap...

0 0 0 0

Sangamo Therapeutics Announces FDA Acceptance of BLA Rolling Submission Request for ST-920 in Fabry Disease Sangamo Therapeutics (Nasdaq: SGMO) announced the FDA has accepted its request for a rolling submission and review of the Biologics License Application (BLA) for isaralgagene civaparvovec (ST-920) for adults with Fabry disease.The FDA reiterated its prior agreement to use eGFR slope as an endpoint to support an accelerated approval pathway. Sangamo said the registrational Phase 1/2 STAAR study showed a positive mean annualized eGFR slope at 52 weeks across dosed patients and that the company plans to initiate rolling BLA submission later in Q4 2025. ST-920 holds multiple regulatory designations including Orphan Drug, Fast Track, RMAT, EMA PRIME and UK Innovative Licensing pathway.

4 months ago

#SGMO Sangamo Therapeutics Announces FDA Acceptance of BLA Rolling Submission Request for ST-920 in Fabry Disease

www.stocktitan.net/news/SGMO/sangamo-therap...

0 0 0 0

Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2025 Financial Results Sangamo Therapeutics (Nasdaq: SGMO) reported Q3 2025 results and program updates on Nov 6, 2025. Key clinical highlights include detailed STAAR registrational data for isaralgagene civaparvovec (ST-920) in Fabry disease showing a positive mean annualized eGFR slope 1.965 mL/min/1.73m2/year at 52 weeks (n=32) and durability of α-Gal A activity up to 4.5 years. FDA reiterated use of eGFR slope to support an accelerated approval pathway; company preparing for a potential BLA as early as Q1 2026. Neurology updates: Phase 1/2 STAND enrollment started for ST-503 with first dosing expected in coming months; ST-506 CTA expected as early as mid-2026. Financials: Q3 net loss $34.9M, revenues $0.6M (vs $49.4M prior year), cash $29.6M as of Sept 30, 2025, with Nasdaq minimum bid extension to April 27, 2026.

5 months ago

#SGMO Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2025 Financial Results

www.stocktitan.net/news/SGMO/sangamo-therap...

0 0 0 0

Văzdooh

@vazdooh.bsky.social

6 months ago

#LXRX & #SGMO joining the pumpers today. Potential for multi day moves.

0 0 1 0

Sangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at International Congress of Inborn Errors of Metabolism 2025 Sangamo Therapeutics (Nasdaq: SGMO) has presented detailed data from its registrational Phase 1/2 STAAR study of isaralgagene civaparvovec (ST-920), a gene therapy for Fabry disease. The study demonstrated a positive mean annualized eGFR slope of 1.965 mL/min/1.73m2/year at 52 weeks across all 32 dosed patients.Key highlights include stable cardiac function, sustained α-Gal A activity for up to 4.5 years, and successful withdrawal of all 18 patients from Enzyme Replacement Therapy (ERT). The therapy showed a favorable safety profile without requiring preconditioning, with mostly grade 1-2 adverse events.Sangamo plans to submit a Biologics License Application (BLA) in Q1 2026 under the Accelerated Approval pathway. The therapy has received multiple regulatory designations, including Fast Track and RMAT from FDA.

7 months ago

#SGMO Sangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at International Congress of Inborn Errors of Metabolism 2025

www.stocktitan.net/news/SGMO/sangamo-therap...

0 0 0 0

Sangamo's Fabry Disease Treatment Shows Breakthrough Results, FDA Fast-Track Potential Ahead of Q2 Earnings Positive topline data from Fabry disease study supports FDA fast-track approval. Q2 revenue jumps to $18.3M with strong pipeline progress. See full results.

8 months ago

#SGMO Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2025 Financial Results

www.stocktitan.net/news/SGMO/sangamo-therap...

0 0 0 0

Genomic Medicine Leader Sangamo Sets Q2 Earnings Call: Key Financial Updates Coming August 7 Genomic medicine pioneer Sangamo announces Q2 2025 earnings call on Aug 7. Join live webcast for latest financial results and business updates. Register now.

8 months ago

#SGMO Sangamo Therapeutics Announces Second Quarter 2025 Earnings Call

www.stocktitan.net/news/SGMO/sangamo-therap...

0 0 0 0

Sangamo Therapeutics Announces Positive Topline Results From Registrational STAAR Study in Fabry Disease Sangamo Therapeutics (Nasdaq: SGMO) announced positive topline results from its registrational Phase 1/2 STAAR study for isaralgagene civaparvovec (ST-920), a gene therapy for Fabry disease. The study demonstrated a positive mean annualized eGFR slope of 1.965 mL/min/1.73m2/year at 52 weeks across all 32 patients, which will serve as the primary basis for FDA approval.Key highlights include maintained elevated α-Gal A activity for up to 4.5 years, successful withdrawal of all 18 patients from enzyme replacement therapy (ERT), and significant improvements in quality of life scores. The therapy showed a favorable safety profile without preconditioning requirements. Sangamo plans to submit a Biologics License Application (BLA) in Q1 2026 under the Accelerated Approval pathway.

9 months ago

#SGMO Sangamo Therapeutics Announces Positive Topline Results From Registrational STAAR Study in Fabry Disease

www.stocktitan.net/news/SGMO/sangamo-therap...

0 0 0 0

Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2025 Financial Results Sangamo Therapeutics (SGMO) reported Q1 2025 financial results and business updates. Key highlights include a new capsid license agreement with Lilly for CNS disease targets, receiving an $18M upfront fee with potential for $1.4B in additional milestone payments. The company achieved significant milestones in its Fabry disease program, with all patients completing 52-week follow-up required for FDA Accelerated Approval pathway. Q1 2025 financial results showed a net loss of $30.6M ($0.14/share), improved from $49.1M loss in Q1 2024. Revenues increased to $6.4M from $0.5M year-over-year. Cash position stands at $25.2M as of March 31, 2025. The company announced a $23M equity offering and expects current funds to support operations into Q3 2025. Sangamo continues to advance its neurology pipeline, including preparations for Phase 1/2 trials in chronic neuropathic pain and prion disease programs.

11 months ago

#SGMO Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2025 Financial Results

www.stocktitan.net/news/SGMO/sangamo-therap...

0 0 0 0

Sangamo Therapeutics Announces Pricing of $23.0 Million Underwritten Offering Sangamo Therapeutics (SGMO) has announced the pricing of a $23.0 million underwritten offering, consisting of 12,235,000 shares of common stock and pre-funded warrants for 34,398,393 shares, along with accompanying warrants to purchase 46,633,393 shares. The pricing is set at $0.50 per share with accompanying warrant, and $0.49 for each pre-funded warrant with accompanying warrant. The accompanying warrants have an exercise price of $0.75 per share, becoming exercisable after six months and expiring in six years. The offering is expected to close around May 14, 2025. Cantor is serving as the sole book-running manager, and Sangamo plans to use the proceeds for working capital and general corporate purposes.

11 months ago

#SGMO Sangamo Therapeutics Announces Pricing of $23.0 Million Underwritten Offering

www.stocktitan.net/news/SGMO/sangamo-therap...

0 0 0 0

Sangamo Therapeutics Postpones First Quarter 2025 Conference Call to Later the Same Day Sangamo Therapeutics (NASDAQ: SGMO) has announced a change in timing for its first quarter 2025 earnings call. The call has been rescheduled from 4:30 p.m. Eastern to 6:30 p.m. Eastern on Monday, May 12, 2025. The registration and access details remain unchanged, with participants able to join via the same previously provided link.Attendees are encouraged to join 10 minutes before the start time and can choose between dialing in with a provided number and passcode or using a dial-out option. The webcast will be available through the Investors and Media section of Sangamo's website, with a replay accessible after the call.

11 months ago

#SGMO Sangamo Therapeutics Postpones First Quarter 2025 Conference Call to Later the Same Day

www.stocktitan.net/news/SGMO/sangamo-therap...

0 0 0 0

PRISM MarketView

@prismmarketview.bsky.social

11 months ago

PRISM Watch: Markets Surge on Tariff Truce, But Uncertainty Lingers
Tariff Truce Fuels Global Market Rally
#AAPL, #AMZN, #NVDA, #TSLA, #CSCO, #BABA, #WMT, #TGT, #SGMO, #AMPY, #OPRX, #MODG, #OCX
prismmarketview.com/prism-watch-...

0 0 0 0

Upcoming Earnings: Genomic Medicine Leader Sangamo Sets Q1 2025 Call Details - How to Join Join Sangamo's Q1 earnings call on May 12 at 4:30 PM ET. Easy registration available for investors to hear latest financial results and business updates. Get access.

11 months ago

#SGMO Sangamo Therapeutics Announces First Quarter 2025 Earnings Call

www.stocktitan.net/news/SGMO/sangamo-therap...

1 0 0 0

Sangamo's Fabry Disease Gene Therapy Hits Critical FDA Milestone, Accelerates Path to 2026 Approval Key FDA milestone reached for ST-920 gene therapy, plus positive eGFR data in Fabry disease treatment. Pivotal readout coming Q2 2025. Get latest updates.

11 months ago

#SGMO Sangamo Therapeutics Announces Important Derisking Milestones in Pathway to Anticipated BLA Submission for ST-920 in Fabry Disease

www.stocktitan.net/news/SGMO/sangamo-therap...

0 0 0 0

11 months ago

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expirations.

AM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#HTZ, #SGMO, #MIRM, #ROOT, #LRN

#OptionFlow #OptionsTrading #Trading

0 0 0 0

11 months ago

🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations!

AM Top Unusual Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #MSTR 74% OTM
2. #HTZ 51% OTM
3. #SGMO 29% OTM
4. #MIRM 29% OTM
5. #ROOT 27% OTM

#OptionFlow #OptionsTrading #Trading

1 1 0 0

Sangamo Therapeutics Announces Capsid License Agreement With Lilly to Deliver Genomic Medicines for Diseases of the Central Nervous System Sangamo Therapeutics (SGMO) has entered into a license agreement with Eli Lilly for its proprietary neurotropic AAV capsid, STAC-BBB, which demonstrates strong blood-brain barrier penetration capabilities. The agreement includes:- An $18 million upfront license fee- Potential earnings of up to $1.4 billion in additional fees and milestone payments across five possible disease targets- Tiered royalties on potential net salesLilly receives worldwide exclusive rights to use STAC-BBB for one initial target, with the option to add four additional targets for treating central nervous system diseases. This marks Sangamo's third agreement since announcing STAC-BBB in March 2024. Sangamo will handle the technology transfer, while Lilly will be responsible for research, development, manufacturing, and commercialization of resulting gene therapy products.

1 year ago

#SGMO Sangamo Therapeutics Announces Capsid License Agreement With Lilly to Deliver Genomic Medicines for Diseases of the Central Nervous System

www.stocktitan.net/news/SGMO/sangamo-therap...

0 0 0 0

@RNAiAnalyst

@rnaianalyst.bsky.social

1 year ago

Piling in more heavily into #SGMO, because:

1) STAC-BBB systemic AAV delivery to CNS: not only data look better than competition, validation through 2 separate deals;

2) #Fabry gene Tx does not require post-infusion steroids, unlike hemoA. Sustained expression, improved QoL.

2 1 0 0

Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results Sangamo Therapeutics (NASDAQ: SGMO) reported key developments and financial results for Q4 and full year 2024. The company secured two significant neurology license agreements: a global epigenetic regulation and capsid delivery agreement with Genentech and a capsid license agreement with Astellas, raising over $100M in non-dilutive funding.Key highlights include: FDA clearance for ST-503 IND for treating intractable pain, with patient enrollment expected mid-2025; successful nonclinical proof of concept in prion disease; and alignment with FDA on Accelerated Approval pathway for isaralgagene civaparvovec in Fabry disease.Financial results show Q4 2024 net loss of $23.4M ($0.11/share) compared to $60.3M loss in Q4 2023. Full-year 2024 net loss was $97.9M versus $257.8M in 2023. Q4 revenues were $7.6M, up from $2.0M in Q4 2023. Cash position stood at $41.9M as of December 31, 2024.

1 year ago

#SGMO Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results

www.stocktitan.net/news/SGMO/sangamo-therap...

0 0 0 0

1 year ago

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expirations.

PM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#SGMO, #NBIS, #SMR, #CVNA, #CNTA

#OptionFlow #OptionsTrading #Trading

0 0 0 0

1 year ago

🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations!

PM Top Unusual Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #MSTR 69% OTM
2. #SOUN 40% OTM
3. #QBTS 40% OTM
4. #SMCI 36% OTM
5. #SGMO 36% OTM

#OptionFlow #OptionsTrading #Trading

0 0 0 0

1 year ago

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expirations.

AM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#CVNA, #QBTS, #SGMO, #SMR, #PDD

#OptionFlow #OptionsTrading #Trading

1 0 1 0